Correction to: Efficacy and Safety of 0.6% Pazufloxacin Ophthalmic Solution Versus Moxifloxacin 0.5% and Gatifloxacin 0.3% in Subjects with Bacterial Conjunctivitis: A Randomized Clinical Trial, by Baiza-Durán, L., Olvera-Montaño, O., Mercado-Sesma, A.R., and Oregon-Miranda, A.A. J Ocul Pharmacol Ther 2018;34(3):250-255. DOI: 10.1089/jop.2017.0056

Ähnliche Einträge

• Correction to: J Ocul Pharmacol Ther 2015;31(7);413–418; DOI: 10.1089/jop.2015.0017
  Veröffentlicht: (2015)
• Correction to: New Therapies to Reduce Intraocular Pressure, by Konda, S.M. and Kaufman, P.L. J Ocul Pharmacol Ther 2019;35(6):322–324. DOI: 10.1089/jop.2019.0059
  Veröffentlicht: (2020)
• Correction to: In Vitro Evaluation of Hybrid Cooperative Complexes of Hyaluronic Acid as a Potential New Ophthalmic Treatment, by La Gatta, A., Corsuto, L., Salzillo, R., D'Agostino, A., De Rosa, M., Bracco, A., and Schiraldi, C. J Ocul Pharmacol Ther 2018;34(10):677–684. DOI: 10.1089/jop.2018.0046
  Veröffentlicht: (2019)
• Correction to: Matrix Metalloproteinases and Glaucoma Treatment, by Weinreb, R.N., Robinson, M.R., Dibas, M. and Stamer, W.D. J Ocul Pharmacol Ther 2020;36(4):208–228. DOI: 10.1089/jop.2019.0146
  Veröffentlicht: (2020)
• Comparison of Drug Concentrations in Human Aqueous Humor after the Administration of 0.3% Gatifloxacin Ophthalmic Gel, 0.3% Gatifloxacin and 0.5% Levofloxacin Ophthalmic Solutions
  von: Ding, Wenting, et al.
  Veröffentlicht: (2015)